secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-05-12T11:35:31+00:00
Accession:  0001104659-26-059009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Q1 net loss $10.7M; $175M April financing; Phase 3 acne trial H2 2026
-----------------------------------------------------------------------------

- Net loss $10.7M for Q1 2026 vs $18.2M in Q1 2025; R&D expense $7.0M (down from $15.3M YoY).
- Cash, cash equivalents and marketable securities $104.5M as of March 31, 2026; expects funding through 2028.
- Completed $175M equity financing in April 2026 (29.2M shares at $6.00) to fund acne programs.
- Plans to initiate U.S. Phase 3 trial of denifanstat in moderate-to-severe acne in second half 2026.
- Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned after completion subject to regulatory consultation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/0001104659-26-059009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer